Study summary
Rituximab helped about 7 in 10 people with inflammatory myositis
70%pooled response rate
What was tested
A pooled analysis of rituximab, a B-cell-depleting antibody, for idiopathic inflammatory myopathies.
What they found
- Pooled response rate was 70%, with complete remission in 13%.
- Responses were similar across myositis subtypes (dermatomyositis 67%).
What it means
Supports rituximab for hard-to-treat myositis, though most evidence is observational.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.